PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)

 In summary, these findings indicate that drug-containing serum of Dahuang Mudan Decoction exhibits effective anti-colorectal cancer activity, promoting cell apoptosis mediated by the PI3K/AKT signaling pathway and participating in the regulation of pathways such as linoleic acid and lipid metabolism. The results underscore the value of Dahuang Mudan Decoction as an important adjunctive therapy for colorectal cancer, proposing new strategies for its treatment.

PIK3R1 overexpression is linked to poor prognosis in GC and influences the extent of immune cell infiltration within the tumor microenvironment. A novel prognostic model integrating PIK3R1 and CD73 expression with clinical parameters was established to stratify GC patients into distinct risk groups, offering potential value for personalized therapeutic strategies.

The 735 gene vascular anomaly/cancer NGS panel is an effective way to detect low levels of somatic mosaicism in these lesions. Given the challenge that many vascular anomalies present to diagnose, genetic testing is an invaluable tool for clinicians to utilize in the process of diagnosis and determining treatment.

Notably, we observed racial disparities in expression patterns, with African American patients exhibiting more pronounced downregulation of p85α and upregulation of p55α than European Americans, potentially contributing to differential clinical outcomes. This is the first study to systematically evaluate p85α and p55α expression across diverse cancers and populations, highlighting the role of alternative splicing in PI3K pathway dysregulation and its relevance to cancer progression and health disparities.

This study establishes significant interspecific flavonoid diversity in Ocimum and demonstrates the multi-target anticancer potential of three key metabolites, directly addressing the limited mechanistic understanding of Ocimum phytochemistry. Our findings provide a foundation for metabolic engineering and accelerate the development of evidence-based Ocimum therapeutics for functional foods and nutraceuticals.

P2, N=7, Terminated, M.D. Anderson Cancer Center | Trial completion date: Feb 2027 --> Dec 2025 | Active, not recruiting --> Terminated; Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.

Combination therapy synergistically downregulated EGFR (0.41- vs. 0.74-fold warfarin, P0.05). The warfarin-bevacizumab combination synergistically impaired PDAC progression via multi-tiered EGFR-PI3K-Akt suppression and mitochondrial apoptosis activation, providing a rationale for clinical translation against oncogenic pathway plasticity.

Animal experiments verified that the JPXK recipe had a good hypoglycemic effect. This study revealed the active ingredients and potential molecular mechanism of the JPXK recipe in the treatment of T2DM, which provides valuable experience in future clinical trials.

Further research to elucidate the clinical impact of ESR1 gene mutations in endometrial cancer are needed. Clinical trials evaluating novel hormonal agents in this patient population are warranted.

The action of L-carnitine against PCOS was mechanistically and pharmacologically implicated with major biological pathways, such as the HIF-1A, PI3K-Akt, and other signaling pathways. These primary predictive biotargets might be used to manage PCOS in the clinical setting after further development.

Integration of molecular sub-group as a stratification parameter might be considered for randomized trials in advanced/metastatic endometrial carcinoma after carboplatin-based chemotherapy. Deeper characterization of mismatch repair-proficient tumors might enhance prognostication.

Translocations occurred in 11 (61.1%) PCL patients; IGH::CCND1 and IGH::MYC were more frequent in PCL compared to MM (22% vs. 14%, p = NS, and 11% vs. 1%, p < 0.05). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.